HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Ovid Therapeutics (NASDAQ:OVID) and maintained a price target of $3.
July 26, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Ovid Therapeutics and maintained a price target of $3, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and the maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. suggests strong confidence in Ovid Therapeutics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100